We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevention of Severe Anaemia in Gambian Children

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00131716
First Posted: August 19, 2005
Last Update Posted: January 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Department of State for Health and Social Welfare, The Gambia
Information provided by (Responsible Party):
Brian Greenwood, London School of Hygiene and Tropical Medicine
  Purpose
Severe anaemia is a frequent cause of admission to hospitals in tropical Africa and about 10% of such children die. In endemic countries, anaemia has multiple causes such as nutritional deficiencies, infections and haemoglobinopathies. However, Plasmodium falciparum infection is believed to be the major contributory factor to the aetiology of severe anaemia. Severe anaemia is usually treated by blood transfusion although transfusion carries the attendant risk of transmission of HIV and other blood-borne infections. Thus, there is a need to explore novel strategies to reduce the incidence of severe anaemia in high-risk groups such as children with suboptimal haemoglobin levels because these children are at increased risk of developing severe anaemia if they develop a malaria infection before their haemoglobin level has normalized. Therefore, it is proposed to study whether monthly chemoprophylaxis with sulphadoxine/pyrimethamine (S/P) given during malaria transmission season can protect Gambian children from developing severe anaemia. After receiving treatment from the hospital, 1200 children admitted to the hospital with a haematocrit of less than 21% were randomised to receive either monthly S/P or placebo during the rest of the malaria transmission season. Morbidity was monitored throughout the rainy season. Study subjects were seen at the end of the dry season to document morbidity and mortality.

Condition Intervention Phase
Anemia Drug: sulfadoxine-pyrimethamine Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Chemoprophylaxis With Sulfadoxine-pyrimethamine to Prevent Recurrence of Severe Anaemia in Gambian Children Aged 3 Months to 9 Years

Resource links provided by NLM:


Further study details as provided by Brian Greenwood, London School of Hygiene and Tropical Medicine:

Primary Outcome Measures:
  • Proportion of children with moderate anaemia (hemoglobin [Hb] <7 g/dl [ Time Frame: at end of the malaria transmission season ]
  • haemoglobin concentration [ Time Frame: At the end of malaria transmission season ]
  • hemoglobin concentration [ Time Frame: at the end of malaria transmission season ]

Secondary Outcome Measures:
  • Proportion of children with anaemia (Hb <11g/dl) and those with severe anaemia (Hb <5 g/dl) [ Time Frame: at end of the malaria transmission season ]
  • Mean Hb : Difference between S/P and placebo, Difference between S/P and placebo adjusted for baseline Hb and other covariates [ Time Frame: at the end of the malaria transmission season ]
  • Number of outpatient department (OPD) attendances with malaria [ Time Frame: during the surveillance period ]
  • Number of hospital admissions with malaria [ Time Frame: during the surveillance period ]
  • Number of episodes of severe malaria [ Time Frame: during the surveillance period ]
  • Deaths (all-cause and malaria-specific) [ Time Frame: during the surveillance period ]
  • Adherence to the study regimen: The number of doses of medication received by children in each group as a proportion of the total number of doses that should have been received [ Time Frame: during the study period ]
  • OPD attendance with malaria [ Time Frame: during the surveillance period ]

Enrollment: 1200
Study Start Date: May 2003
Estimated Study Completion Date: May 2005
  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   3 Months to 9 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age: 3 months to 9 years.
  2. Haemoglobin concentration 7g/dl on admission to hospital.
  3. Residence within 30 km of the study centre and availability for the duration of the study period.
  4. Informed consent to participate in the study given by the parent or guardian.

Exclusion Criteria:

  1. Simultaneous participation in any other trial.
  2. Allergy to sulpha drugs.
  3. Residence > 30 km from the recruitment site.
  4. Lack of consent.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00131716


Locations
Gambia
Medical Research Council Laboratories,
Banjul, Gambia
Sponsors and Collaborators
London School of Hygiene and Tropical Medicine
Department of State for Health and Social Welfare, The Gambia
Investigators
Study Chair: Brian Greenwood, MD London School of Hygiene and Tropical Medicine
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Brian Greenwood, Professor, London School of Hygiene and Tropical Medicine
ClinicalTrials.gov Identifier: NCT00131716     History of Changes
Other Study ID Numbers: ITCRVG33.
First Submitted: August 18, 2005
First Posted: August 19, 2005
Last Update Posted: January 12, 2017
Last Verified: January 2017

Keywords provided by Brian Greenwood, London School of Hygiene and Tropical Medicine:
prevention
recurrence
severe
anaemia

Additional relevant MeSH terms:
Anemia
Hematologic Diseases
Pyrimethamine
Sulfadoxine
Fanasil, pyrimethamine drug combination
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Infective Agents, Urinary
Renal Agents